Boehringer Ingelheim, a global leader in the pharmaceutical industry, has entered into a strategic partnership with the Saudi Health Council (SHC) to advance mental health services in Saudi Arabia. The collaboration, formalized through a memorandum of understanding (MoU) signed on December 12, 2024, aims to enhance mental health policies and services in alignment with Saudi Arabia’s Vision 2030.
The MoU was signed by Dr. Mushabab Al-Assiri, acting director general of health economics and policies at SHC, and Abdallah Hamed, general manager and head of human pharma Saudi Arabia, Gulf, and East Africa at Boehringer Ingelheim. The agreement marks a significant step toward improving the mental health landscape in Saudi Arabia by fostering innovation, promoting awareness, and integrating the latest research and treatment models.
In a statement, Abdallah Hamed emphasized Boehringer Ingelheim’s ongoing commitment to strengthening collaborations with public sector entities. He noted that the partnership with the SHC is part of their mission to create science-based solutions that support both patients and healthcare systems in the Kingdom. “We are proud to support Saudi Arabia’s Vision 2030 and contribute to the development of a more robust mental health ecosystem that addresses the needs of the community,” said Hamed.
This partnership highlights the importance of cooperation between the public and private sectors to achieve shared goals in advancing national health agendas. The long-term objectives of the collaboration focus on developing comprehensive policies to address mental health needs, enhancing public awareness, reducing stigma, and improving access to care through evidence-based practices.
By aligning with policymakers, healthcare professionals, and patient advocacy groups, the partnership aims to create a more inclusive and effective mental health care system that provides better clinical outcomes and improves overall well-being for the population.
Related topics:
